Sponsor

Eastern Cooperative Oncology Group

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Eastern Cooperative Oncology Group appears in 85 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials85
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)NCT07122492 · lead sponsor · 2025-09-01
NOT_YET_RECRUITING
Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion ProtocolNCT06786585 · lead sponsor · 2025-06-01
NOT_YET_RECRUITING
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) ParticipationNCT05076266 · lead sponsor · 2022-03-14
TERMINATED
PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802NCT01672905 · lead sponsor · 2012-12-07
COMPLETED
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast CancerNCT01242800 · lead sponsor · 2011-05-16
COMPLETED
Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate CancerNCT00685633 · lead sponsor · 2008-12-01
WITHDRAWN
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate CancerNCT00771017 · lead sponsor · 2008-07-01
WITHDRAWN
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung CancerNCT00469976 · lead sponsor · 2007-06-01
WITHDRAWN
Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerNCT00387699 · lead sponsor · 2006-10-01
COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid TumorsNCT00499291 · lead sponsor · 2006-09-01
WITHDRAWN
Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100NCT00899418 · lead sponsor · 2006-05-01
COMPLETED
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or AcquaintanceNCT00309933 · lead sponsor · 2006-04-03
COMPLETED
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal CancerNCT00303914 · lead sponsor · 2006-03-14
COMPLETED
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural MesotheliomaNCT00101283 · lead sponsor · 2006-02-23
COMPLETED
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung CancerNCT00080938 · lead sponsor · 2005-12-20
COMPLETED
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung CancerNCT00103207 · lead sponsor · 2005-10-13
COMPLETED
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With ChemotherapyNCT00897299 · lead sponsor · 2005-10-07
COMPLETED
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast CancerNCT00090974 · lead sponsor · 2005-01-26
COMPLETED
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate CancerNCT00060398 · lead sponsor · 2004-09-29
COMPLETED
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00057837 · lead sponsor · 2004-07-14
COMPLETED
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung CancerNCT00064350 · lead sponsor · 2004-06-28
COMPLETED
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung CancerNCT00062010 · lead sponsor · 2004-05-26
COMPLETED
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate CancerNCT00027859 · lead sponsor · 2003-10-08
COMPLETED
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung CancerNCT00041314 · lead sponsor · 2002-10-04
COMPLETED
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast CancerNCT00028990 · lead sponsor · 2002-01-29
COMPLETED
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyNCT00005847 · lead sponsor · 2001-04-05
COMPLETED
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast CancerNCT00026286 · lead sponsor · 2000-11-28
COMPLETED
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung CancerNCT00006004 · lead sponsor · 2000-08-22
COMPLETED
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung CancerNCT00004225 · lead sponsor · 2000-01-01
COMPLETED
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph NodesNCT00004125 · lead sponsor · 1999-11-16
COMPLETED
PSA Vaccine Therapy in Treating Patients With Advanced Prostate CancerNCT00003871 · lead sponsor · 1999-09-24
COMPLETED
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung CancerNCT00003881 · lead sponsor · 1999-05-01
COMPLETED
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerNCT00003614 · lead sponsor · 1999-02-04
COMPLETED
Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically RemovedNCT00003649 · lead sponsor · 1998-11-17
COMPLETED
Combination Chemotherapy in Treating Women With Breast CancerNCT00003519 · lead sponsor · 1998-08-20
COMPLETED
Chemotherapy in Treating Women With Previously Treated Metastatic Breast CancerNCT00003236 · lead sponsor · 1998-07-13
COMPLETED
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically RemovedNCT00003235 · lead sponsor · 1998-06-01
COMPLETED
Identification of Genes Associated With Cancer in Patients and Siblings Who Have CancerNCT00003329 · lead sponsor · 1998-04-07
COMPLETED
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following ChemotherapyNCT00003010 · lead sponsor · 1997-12-02
COMPLETED
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast CancerNCT00002826 · lead sponsor · 1997-08-14
COMPLETED
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In SituNCT00002934 · lead sponsor · 1997-06-25
TERMINATED
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate CancerNCT00002881 · lead sponsor · 1996-10-01
COMPLETED
Pain Control in Patients With Recurrent or Metastatic Breast or Prostate CancerNCT00002668 · lead sponsor · 1996-02-14
TERMINATED
Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung CancerNCT00002667 · lead sponsor · 1995-10-10
COMPLETED
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast CancerNCT00002646 · lead sponsor · 1995-10-01
COMPLETED
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage CancerNCT00002520 · lead sponsor · 1990-12-07
COMPLETED
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerNCT05705401 · collaborator · 2023-05-19
ACTIVE_NOT_RECRUITING
SMART-ER: Symptom Monitoring With Patient-reported OutcomesNCT05560685 · collaborator · 2022-10-03
TERMINATED
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerNCT03488693 · collaborator · 2018-10-16
ACTIVE_NOT_RECRUITING
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In SituNCT02352883 · collaborator · 2015-03-25
ACTIVE_NOT_RECRUITING
Tomosynthesis Mammographic Imaging Screening TrialNCT02616432 · collaborator · 2014-10-01
ACTIVE_NOT_RECRUITING
DCE-MRI and DWI for Detection and Diagnosis of Breast CancerNCT02022579 · collaborator · 2014-01-01
UNKNOWN
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerNCT00738881 · collaborator · 2008-10-01
TERMINATED
Observation or Radical Treatment in Patients With Prostate CancerNCT00499174 · collaborator · 2007-12-06
TERMINATED
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerNCT00433511 · collaborator · 2007-11-02
ACTIVE_NOT_RECRUITING
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate CancerNCT00430183 · collaborator · 2007-05-08
ACTIVE_NOT_RECRUITING
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.NCT00127205 · collaborator · 2005-07-01
COMPLETED
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung CancerNCT00113386 · collaborator · 2005-04-01
TERMINATED
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor TherapyNCT00754845 · collaborator · 2004-11-23
COMPLETED
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone MetastasesNCT00079001 · collaborator · 2004-01-01
COMPLETED

Sponsor roles

lead sponsor46
collaborator39
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.